Blog » Guest Articles » Immunoglobulin Industry: High Prevalence of Primary Immunodeficiency to Foster Growth
immunoglobulin industry

Immunoglobulin Industry: High Prevalence of Primary Immunodeficiency to Foster Growth

Upgrade in Intervention Technology to Propel Growth

The increasing cases of chronic inflammatory demyelinating polyneuropathy (CIDP) and primary immunodeficiency (PI) are the major factors anticipated to drive the global immunoglobulin Industry. Furthermore, technological upgrades in the administration methods are likely to fuel the demand for immunoglobulin test and structure.

CUVITRU, a subcutaneous immunoglobulin introduced by the Shire to facilitate the treatment of primary immunodeficiency, is the only 20% subcutaneous immunoglobulin in the U.S. without proline. Such launches are likely to enable growth in the global immunoglobulin Industry.

However, high costs associated with immunoglobulin and side-effects associated with immunoglobulins are a few key factors that may restrain the market.

In terms of region, North America is foreseen to emerge dominant over the forecast period. The region also held a major share in the market in 2017. The North America immunoglobulin Industry was worth US$ 6,291.5 Mn in 2017. Immunoglobulin is the most popular treatment available for various immune disorders. Moreover, the number of patients in the region is increasing. These factors are anticipated to contribute to market growth.

immunoglobulin industry

Top companies Covered in the immunoglobulin Industry:

  • CSL Behring
  • Grifols
  • Kedrion Biopharma
  • Octapharma
  • Bio Products Laboratory Ltd
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • LFB SA and Shanghai RAAS Blood Products Co., Ltd.

On the basis of route of administration, the market is bifurcated into intravenous and subcutaneous. The intravenous segment accounted for the largest share of the global market in 2017. Intravenous is foreseen to hold its position as the dominant segment through the forecast period 2018-2025. However, the segment’s growth is likely to decelerate during the forecast period. Meanwhile, frequent product launches will enable growth in the subcutaneous segment.

Additionally, a rising emphasis on diagnosis and treatment of immune disease is anticipated to fuel demand in the overall market.

Shire to Gain from CUVITRU’s Approval

The competition in the global immunoglobulin Industry is increasing owing to the prevailing opportunities. In 2017 Grifols, S.A. was leading the global market. Grifols owns a diverse product portfolio and that is helping the organization to have major gains. The company holds a major share in various regional markets also.

Grifols, S.A., holds the highest share in Europe and North America immunoglobulin Industry. Besides this, other players are also focusing on product innovation to gain momentum. For instance, Shire received approval for CUVITRU. Such innovation and increasing competition are expected to propel growth in the market.

Also, read about Healthy Chocolate Bar Intended To Gain Competitive Advantage

Author Profile

Tanay Bhalla is a part of the very talented content team at Fortune Business Insights. He is a highly-driven writer with extensive experience in market research. Tanay specializes in blogs, articles and press releases. His approach to writing is simple, intended to ensure a seamless read.

For any health-related queries or information on women’s health, speak to Credihealth medical expert at +918010994994

Request Callback

Need Guidance in choosing right doctor?

REQUEST CALLBACK
Subscribe